20:11 , Nov 26, 2018 |  BC Innovations  |  Distillery Therapeutics

Transplant

INDICATION: Heart transplant rejection Mouse studies suggest APOA/phospholipid-based nanoparticles loaded with rapamycin or a TRAF6 inhibitor could help prevent heart transplant rejection. The nanoparticles consist of APOA and natural phospholipid components of HDL cholesterol isolated...
17:37 , Jul 17, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Breast cancer, melanoma, lung cancer Mouse studies suggest a phospholipid-conjugated TLR7 agonist could help treat metastatic breast cancer, melanoma and lung cancer. The conjugate consists of a previously identified purine-based TLR7 agonist linked to...
00:33 , Apr 6, 2018 |  BC Innovations  |  Targets & Mechanisms

GI Band-Aid

A trio of Science papers shows a leaky gut can drive systemic inflammation and autoimmunity by allowing bacteria and their products to escape the GI lumen and enter the bloodstream. The results open a variety...
22:06 , Jan 9, 2018 |  BC Innovations  |  Distillery Therapeutics

Infectious disease

INDICATION: Bacterial infection; Escherichia; Pseudomonas; Salmonella Cell culture studies suggest engineered virus-like capsids could be used to treat a range of bacterial infections. The capsids consist of 21- and 23-mer peptide sequences designed to self-assemble...
19:47 , Oct 13, 2017 |  BC Week In Review  |  Company News

Cellectar and Pierre Fabre extend PDC deal

Cellectar Biosciences Inc. (NASDAQ:CLRB) and Pierre Fabre Group (Castres, France) extended a 2015 deal to develop phospholipid drug conjugates (PDC) to treat cancer. The companies said the extension will cover combining Pierre Fabre's cytotoxic payloads...
19:30 , Sep 11, 2017 |  BC Innovations  |  Distillery Techniques

Drug delivery

TECHNOLOGY: Nanoparticles Integrin β3 -targeted nanoparticles could deliver chemotherapies to treat bone metastases of breast cancer. The nanoparticles consist of phospholipid/polysorbate 80 micelles loaded with drug and coated with an integrin αvβ3 ( CD51/CD61 )-binding...
15:53 , Mar 28, 2017 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Spinal cord injury (SCI) Cell culture and mouse studies suggest promoting LPPR1 expression or inhibiting LPAR1 could help treat SCI. In primary mouse cortical neurons subjected to scrape injury, overexpression of LPPR1 increased regeneration...
23:26 , Nov 10, 2016 |  BC Week In Review  |  Clinical News

MDCO-216: Development discontinued

The Medicines Co. said it will discontinue development of MDCO-216 after it failed to show efficacy at reducing intracoronary atherosclerotic plaque burden in the double-blind, placebo-controlled, international Phase I/II MILANO-PILOT trial. MILANO-PILOT was evaluating 20...
00:11 , Nov 9, 2016 |  BC Extra  |  Clinical News

Medicines Co. ending CV program MDCO-216

The Medicines Co. (NASDAQ:MDCO) said it will discontinue development of MDCO-216 after it failed to show efficacy at reducing intracoronary atherosclerotic plaque burden in the proof-of-concept Phase I/II MILANO-PILOT study, which enrolled patients with acute...
07:00 , Sep 26, 2016 |  BC Week In Review  |  Clinical News

BXQ-350: Phase I started

Bexion began an open-label, U.S. Phase I trial to evaluate IV BXQ-350 in about 40 patients, including those with recurrent high-grade gliomas. A dose-escalation part will identify the dose to be used in the second...